Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Susan DababouSimone GarzonAntonio Simone LaganàSimone FerreroGiulio EvangelistiMarco NoventaMaurizio Nicola D'AlterioStefano PalombaStefano UccellaMassimo FranchiFabio BarraPublished in: Expert opinion on investigational drugs (2021)
Linzagolix showed a dose-dependent and rapidly reversible action on the pituitary-gonadal axis. In a recent phase II trial (EDELWEISS), linzagolix significantly reduced pain related to endometriosis and improved quality of life at single daily doses of 75-200 mg. The preliminary results of international, double-blind phase III trials (PRIMROSE 1 and 2) reported its efficacy in treating heavy menstrual bleeding related to myomas with a good safety profile. Further studies will determine the necessity of add-back therapy during long-term use of linzagolix.